Comparison of the Non-Nucleoside Reverse Transcriptase Inhibitor Lersivirine with its Pyrazole and Imidazole Isomers

Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1

(2010) R. Corbau et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Crystal Structures of HIV-1 Reverse Transcriptase with Etravirine (TMC125) and Rilpivirine (TMC278): Implications for Drug Design

(2010) Eric B. Lansdon et al.   JOURNAL OF MEDICINAL CHEMISTRY

Aromatic chloride to nitrile transformation: medicinal and synthetic chemistry

(2010) Lyn H. Jones et al.   MedChemComm

Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients

(2009) Gerd Fätkenheuer et al.   AIDS

Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate

(2009) Charles E. Mowbray et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis

(2009) Thomas Ryckmans et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Novel Indazole Non-Nucleoside Reverse Transcriptase Inhibitors Using Molecular Hybridization Based on Crystallographic Overlays†

(2009) Lyn H. Jones et al.   JOURNAL OF MEDICINAL CHEMISTRY

Elucidating the Inhibition Mechanism of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors through Multicopy Molecular Dynamics Simulations

(2009) Anthony Ivetac et al.   JOURNAL OF MOLECULAR BIOLOGY

Optimization of 5-Aryloxyimidazole Non-Nucleoside Reverse Transcriptase Inhibitors

(2008) Lyn H. Jones et al.   ChemMedChem

Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use ofin silicophysiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man

(2008) G. Allan et al.   XENOBIOTICA